Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, joboggi, Sir Francelote, zoomboom, Rosym
Search This Board:
Last Post: 11/26/2014 9:12:27 PM - Followers: 718 - Board type: Free - Posts Today: 0

                Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

For further information, please visit www.Amarantus.comor connect with the company on FacebookTwitter, LinkedIn & Google+



Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
Nov. 25, 2014
Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014
Live Webcast of Presentation on Tuesday, December 2, 2014 at 10:30 a.m. PST / 1:30 p.m. EST -  Nov. 24, 2014
Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
Nov. 20, 2014
Astute Deal Brings In Another Shot On Goal For Amarantus Bio
By Jason Napodano, CFA -  November 19, 2014
Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
Nov 19, 2014    12:46 p.m.     
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza

Nov 17, 2014    4:20 p.m.
Amarantus to Host Business Update Conference Call on November 18, 2014
Nov 17, 2014    8:02 a.m. 
Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing
Nov 10, 2014    6:01 a.m. 
OCTOBER 29, 2014 
Eltoprazine, LymPro and MANF: The Path Forward to Value Creation
 October 27, 2014    8:00 am
Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Oct 20, 2014 8:01 a.m.
Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Also in Cramer's Portfolio: Amarantus Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa 

Oct 16, 2014   9:30 a.m.
Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Oct 9, 2014    6:01 a.m.
Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct 7, 2014    8:01 a.m.
Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024 : Opportunities for Leading Companies
Oct 1, 2014    9:16 p.m.
Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sept 29, 2014     2:04 p.m.

Amarantus BioScience (Documentary Trailer)

Oct. 19, 2014
SNNLive - Amarantus  BioScience Holdings, Inc.
  Published on June 21, 2014



Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc

408-737-2734 x101

VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols

Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179


smiley  Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe AD cohort of 140 subjects (initial 72 patients + 68 patient extension) by year-end 2014, and make a final determination on which assay conditions (Version 1 vs. Version 2) it will use to support its product launch.   cool

smiley  "Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community by the year-end 2014. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
   Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen” 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.

Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014

- Live Webcast of Presentation on Tuesday, December 2, 2014 at 10:30 a.m. PST / 1:30 p.m. EST -

Gerald E. Commissiong, President and Chief Executive Officer, will present at the LD Micro Main Event VII micro-cap investor conference being held December 2 - 4, 2014 at the Luxe Sunset Hotel in Los Angeles, California.

Mr. Commissiong will present on Tuesday, December 2, 2014 at 10:30 a.m. PST (1:30 p.m. EST) and will provide an update on Amarantus' recent corporate milestone achievements, clinical development progress and expected near-term catalysts.
Amarantus to Present at the LD Micro
Main Event VII Investor Conference on
December 2, 2014


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Current Report Filing (8-k) 11/24/2014 06:07:58 AM
AMBS News: Statement of Changes in Beneficial Ownership (4) 11/20/2014 01:17:24 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 11/20/2014 12:28:34 PM
AMBS News: Current Report Filing (8-k) 11/17/2014 05:24:20 PM
AMBS News: Small Company Offering and Sale of Securities Without Registration (d) 11/17/2014 05:03:16 PM
#109587  Sticky Note JN - Why I'm Still Optimistic On LymPro Rosym 10/25/14 09:00:15 AM
#108674  Sticky Note Update from ASM Meeting: Sir Francelote 09/23/14 08:44:23 AM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#110061   Happy thanksgiving and to the non Americans happy shamalam 11/26/14 09:12:27 PM
#110060 GS1 11/26/14 06:40:54 PM
#110059 GS1 11/26/14 06:28:56 PM
#110058   There were signs that more than management were brharris 11/26/14 01:33:14 PM
#110057   great timing on management buying before the news porsche2006 11/26/14 01:07:42 PM
#110056   strong bids are moving up....we now have more Alapis 11/26/14 01:01:17 PM
#110055   i remember... not enough rats to get stat macnqueso 11/26/14 12:32:36 PM
#110054   Indeed, a most interesting observation. It would Aqua 11/26/14 10:45:12 AM
#110053   Good to hear and it's always wise to brharris 11/26/14 10:44:27 AM
#110052   that would be fine. I suspect that it joboggi 11/26/14 10:43:59 AM
#110051   Re: getting off at the peak means you shamalam 11/26/14 10:42:10 AM
#110050   no doubt, I am playing along. And then joboggi 11/26/14 10:34:22 AM
#110049   I will leave the science to the professionals. brharris 11/26/14 10:26:19 AM
#110048   You guys did not even get a sen joboggi 11/26/14 10:15:37 AM
#110047   .093x.094 nice volume for today! a surfer 11/26/14 09:50:10 AM
#110046   there is NO other small cap biotech i'm Alapis 11/26/14 09:10:53 AM
#110045   For someone to come on a message board brharris 11/26/14 08:58:56 AM
#110044   brharris - Joboggi says "ambs has a history michelebucks 11/26/14 08:38:15 AM
#110043   guardiangel you said: GetSeriousOK 11/26/14 08:21:43 AM
#110042 GS1 11/26/14 03:13:30 AM
#110041   Joboggi one thing I don't understand. You have sante1 11/26/14 12:29:26 AM
#110040   Reminder! Amarantus to Present at the LD Micro sante1 11/26/14 12:06:13 AM
#110039   I agree completely. You only uplist from position GS1 11/25/14 10:35:27 PM
#110036   You're really going to question the work of brharris 11/25/14 05:52:13 PM
#110035   .10 tomorrow close would be a great way TekNerd 11/25/14 05:49:35 PM
#110034   "The experiments were conducted at a leading ophthalmology joboggi 11/25/14 05:12:02 PM
#110031   Sierra World Equity Review Harry von Zell 11/25/14 03:04:32 PM
#110030   AMBS has historically made some nice moves in brharris 11/25/14 11:19:54 AM
#110029   Let her rip. Cheers! Aqua 11/25/14 10:07:26 AM
#110028   Looks like the market is ready to let a surfer 11/25/14 09:47:47 AM
#110027   News release: zynomat 11/25/14 09:43:48 AM
#110025   Wow, GC and Team are silencing step by christjamin 11/25/14 06:51:58 AM
#110024   Good point. More bidders are better so the GS1 11/25/14 01:18:48 AM
#110023   Amarantus Applies to FDA for MANF Orphan Drug GS1 11/25/14 12:29:23 AM
#110022   Thanks joboggi for your thoughts. dh4systems 11/24/14 11:19:35 PM
#110020   Right, no fda in europe. But you might Angry Goat 11/24/14 07:22:59 PM
#110019   Win-Win for both companies. Reginicin will use this GS1 11/24/14 05:44:36 PM
#110018   Nice close goldia 11/24/14 04:07:56 PM
#110017   So what does this do to the stock. brianc22 11/24/14 01:56:16 PM
#110016   Yes very nice volume. The chart player will brharris 11/24/14 01:18:28 PM
#110015   Liking the volume this morning. Investors are noticing. Goldstrike 11/24/14 01:14:04 PM
#110014   Are going test the 9's myersvodka 11/24/14 12:45:07 PM
#110013   The writing is on the wall for anyone brharris 11/24/14 11:24:13 AM
#110012   From the 8-K Filling sante1 11/24/14 10:35:55 AM
#110011   Setting up the launch pad myersvodka 11/24/14 10:09:54 AM
#110010   Absolutely. Europe = no FDA Once again AMBS team brharris 11/24/14 10:03:33 AM
#110009   This is a confirmation that Europe is going Sir Francelote 11/24/14 09:28:54 AM
#110008   Indeed they are. AMBS is spreading their wings: Effective brharris 11/24/14 09:23:40 AM
#110007   Excellent. All pieces are falling into place. Sir Francelote 11/24/14 09:17:34 AM
#110006   Nice news!! Dr Lowe now President of brharris 11/24/14 09:09:43 AM